Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice

International Journal of Cancer

Volumn 87, Issue 5, 2000, Pages 688-694

  Kurt, Robert A ^a,c   Whitaker, Rachel ^a,c   Baher, Anjelo ^a   Seung, Steven ^b   Urba, Walter J ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c Cellular Immunology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CYTOKINE RELEASE; IMMUNE RESPONSE; IMMUNOGENICITY; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR REJECTION; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CYTOKINES; DISEASE MODELS, ANIMAL; GENES, ERBB-2; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNE TOLERANCE; INTERLEUKIN-2; ISOANTIGENS; L-SELECTIN; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; RATS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0033862302     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000901)87:5<688::AID-IJC11>3.0.CO;2-E     Document Type: Article

References (18)

1. AMICI, A., VENANZI, F.M. and CONCETTI, A., Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol. Immunother., 47, 183-190 (1998).
2. BAKKER, A.B., SCHREURS, M.W., DEBOER, A.J., KAWAKAMI, Y., ROSENBERG, S.A., ADEMA, G.J. and FIGDOR, C.G., Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179, 1005-1009 (1994).
3. BOON, T. and VAN DER BUGGEN, P., Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183, 725-729 (1996).
4. CELIS, E., TSAI, V., CRIMI, C., DEMARS, R., WENTWORTH, P.A., CHESTNUT, R.W., GREY, H.M., SETTE, A. and SERRA, H.M., Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. nat. Acad. Sci. (Wash.). 15, 2105-2109 (1994).
5. DISIS, M.L., CALENOF, E., MCLAUGHLIN, G., MURPHY, A.E., CHEN, W., GRONER, B., JESCHKE, M., LYDON, N., MCGLYNN, E., LIVINGSTON, R.B., MOE and CHEEVER, M.A., Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54, 16-20 (1994).
6. DUBOIS, N., BENNOUS, M., ALLEMAND, I., MOLINA, T., GRIMBER, G., DAUDET-MONSAC, M., ABELANET, R. and BRIAND, P., Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J. Hepatol., 13, 227-239 (1991).
7. FINKE, J.H., ZEA, A.H., STANELY, J., LONGO, D.L., MIZOGUCHI, H., TUBBS, R.R., WILTROUT, R.H., O'SHEA, J.J., KUDOH, S., KLEIN, E., BUKOWSKI, R.M. and OCHOA, A.C., Loss of T-cell receptor z chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 53, 5613-5616 (1993).
8. GANSS, R. and HANAHAN, D., Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res., 58, 4673-4681 (1998).
9. GREENBERG, N.M., DEMAYO, F., FINEGOLD, M.J., MEDINA, D., TILLEY, W.D., ASPINALL, J.O., CUNHA, G.R., DONJACOUR, A.A., MATUSIK, R.J. and ROSEN, J.M., Prostate cancer in a transgenic mouse. Proc. nat. Acad. Sci.(Wash.), 92, 3439-3443 (1995).
10. GUY, C.T., WEBSTER, M.A., SCHALLER, M., PARSONS, T.J., CARL, R.D. and MULLER, W.J., Expression of the neu protooncogene in the mammary epithelium transgenic mice induces metastatic disease. Proc. nat. Acad. Sci. (Wash.), 89, 10578-10582 (1992).
11. HANAHAN, D., Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature, 315, 115-122 (1985).
12. HU, H.M., URBA, W.J. and FOX, B.A., Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 161, 3033-3041 (1998).
13. KASS, E., SCHLOM, J., THOMPSON, J., GUADAGNI, F., GRAZIANO, P. and GREINER, J.W., Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res., 59, 676-683 (1999).
14. KURT, R.A., PARK, J.A., PANELLI, M.C., SCHLUTER, S.F., MARCHALONIS, J.J., CAROLUS, B. and AKPORIAYE, E.T., T lymphocytes infiltrating sites of tumor rejection and progression display identical Vβ usage but different cytotoxic activities. J. Immunol., 154, 3969-3974 (1995).
15. KURT, R.A., URBA, W.J., SMITH, J.W. and SCHOOF, D.D., Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int. J. Cancer, 78, 16-20 (1998).
16. MIZOGUCHI, H., O'SHEA, J.J., LONGO, D.L., LOEFFLER, C.M., MCVICAR, D.W. and OCHOA, A.C., Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science, 258, 1795-1798 (1992).
17. MOREL, A., COSTE, A., FERNANDEZ., N., BERSON, A., KAYBANDA, M., MOLINA, T., BRIAND, P., HADDADA, H., GUILLET, J., ANTOINE, B., VIGUIER, M. and KAHN, A., Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice? Cancer Gene Ther., 5, 92-100 (1998).
18. + lymphocytes provide MUCl-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUCl transgenc mice. J. Immunol., 161, 5500-5506 (1998).